货号:A208207 同义名: 左旋甲状腺素钠 / T4 sodium;Levothyroxine sodium
L-Thyroxine Sodium is the major hormone derived from the thyroid gland.
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
描述 | L-Thyroxine sodium (Levothyroxine sodium) is a synthetic hormone for the research of hypothyroidism[3]. The topic of pharmacological interference on L-T4 (L-thyroxine) therapy addresses the patient with primary hypothyroidism, in whom periodic measurement of serum thyrotropin (TSH) is the biochemical target[4]. Compared with L-T4 alone, replacement therapy with the combination of L-T4+L-T3 (L-triiodothyronine) shows favourable changes in serum lipid profile, but higher activation of bone resorption[5]. Standard L-thyroxine supplementation in HT (Hashimoto's thyroiditis) patients exerted significant immunoregulatory effects, associated with quantitative and phenotypic changes of peripheral blood DC (dendritic cells) subpopulations[6]. The thyroid hormone affects ventricular inhomogenicity, and that L-thyroxine replacement therapy may reduce malignant ventricular arrhythmia and sudden cardiac death in primary hypothyroidism[7]. |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT03693612 | Neoplasms | Phase 1 Phase 2 | Recruiting | June 16, 2022 | United States, Massachusetts ... 展开 >> GSK Investigational Site Not yet recruiting Boston, Massachusetts, United States, 02215 Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com Contact: EU GSK Clinical Trials Call Centre 877-379-3718 GSKClinicalSupportHD@gsk.com United States, New York GSK Investigational Site Not yet recruiting New York, New York, United States, 10016- Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com Contact: EU GSK Clinical Trials Call Centre 877-379-3718 GSKClinicalSupportHD@gsk.com GSK Investigational Site Not yet recruiting New York, New York, United States, 10032 Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com Contact: EU GSK Clinical Trials Call Centre 877-379-3718 GSKClinicalSupportHD@gsk.com United States, Oklahoma GSK Investigational Site Not yet recruiting Oklahoma City, Oklahoma, United States, 73104 Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com Contact: EU GSK Clinical Trials Call Centre 877-379-3718 GSKClinicalSupportHD@gsk.com United States, Pennsylvania GSK Investigational Site Not yet recruiting Pittsburgh, Pennsylvania, United States, 15232 Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com Contact: EU GSK Clinical Trials Call Centre 877-379-3718 GSKClinicalSupportHD@gsk.com United States, Texas GSK Investigational Site Recruiting San Antonio, Texas, United States, 78240 Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com Contact: EU GSK Clinical Trials Call Centre 877-379-3718 GSKClinicalSupportHD@gsk.com Principal Investigator: Anthony Tolcher Australia, New South Wales GSK Investigational Site Not yet recruiting Darlinghurst, New South Wales, Australia, 2010 Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com Contact: EU GSK Clinical Trials Call Centre 877-379-3718 GSKClinicalSupportHD@gsk.com Australia, Victoria GSK Investigational Site Not yet recruiting Melbourne, Victoria, Australia, 3000 Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com Contact: EU GSK Clinical Trials Call Centre 877-379-3718 GSKClinicalSupportHD@gsk.com Canada, Ontario GSK Investigational Site Not yet recruiting Ottawa, Ontario, Canada, K1H 8L Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com Contact: EU GSK Clinical Trials Call Centre 877-379-3718 GSKClinicalSupportHD@gsk.com GSK Investigational Site Not yet recruiting Toronto, Ontario, Canada, M5G 2M Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com Contact: EU GSK Clinical Trials Call Centre 877-379-3718 GSKClinicalSupportHD@gsk.com 收起 << |
NCT00945282 | Infection, Human Immunodeficie... 展开 >>ncy Virus 收起 << | Phase 2 | Completed | - | Argentina ... 展开 >> GSK Investigational Site Buenos Aires, Argentina, B1602DBG 收起 << |
NCT02705807 | Cardiovascular Disease | Phase 4 | Completed | - | Japan ... 展开 >> GSK Investigational Site Okayama, Japan, 701-1192 收起 << |
计算器 | ||||
存储液制备 | 1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
1.25mL 0.25mL 0.13mL |
6.26mL 1.25mL 0.63mL |
12.52mL 2.50mL 1.25mL |
CAS号 | 55-03-8 |
分子式 | C15H10I4NNaO4 |
分子量 | 798.852 |
别名 | 左旋甲状腺素钠 ;T4 sodium;Levothyroxine sodium;L-T4 sodium |
运输 | 蓝冰 |
存储条件 |
液体 -20°C:3-6个月-80°C:12个月 粉末 Keep in dark place,Inert atmosphere,Room temperature |
溶解度 |
DMSO: 60 mg/mL(75.11 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO H2O: 14 mg/mL(17.53 mM),配合低频超声,并调节pH至11 |
动物实验配方 |